ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

November 27, 2007 14:14 ET

ART Advanced Research Technologies Sponsors the Fourth Annual CHI Molecular Imaging Week Meetings in San Diego, CA

MONTREAL, CANADA--(Marketwire - Nov. 27, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is sponsoring the fourth annual CHI Molecular Imaging Week meetings in San Diego, California. These meetings will focus on in vitro and in vivo applications of molecular imaging and present novel techniques that are helping to bridge the gap from discovery to clinical applications. Topics include optical imaging, imaging biomarkers, imaging of clinical responses, functional imaging and challenges faced by various molecular imaging modalities, to name a few. The event will be held at the Hyatt Regency Mission Bay Hotel in San Diego from November 27 to 30, 2007.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (

Contact Information